Bryan A. Faller

3.7k total citations · 1 hit paper
32 papers, 532 citations indexed

About

Bryan A. Faller is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Bryan A. Faller has authored 32 papers receiving a total of 532 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 8 papers in Molecular Biology. Recurrent topics in Bryan A. Faller's work include Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Bryan A. Faller is often cited by papers focused on Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Diagnosis and Treatment (8 papers) and Cancer Immunotherapy and Biomarkers (7 papers). Bryan A. Faller collaborates with scholars based in United States, Ireland and Greece. Bryan A. Faller's co-authors include Barbara Burtness, Mary W. Redman, Karen Kelly, Karen L. Reckamp, David R. Gandara, Roy S. Herbst, Tareq Al Baghdadi, Jhanelle E. Gray, Katherine Minichiello and Saiama N. Waqar and has published in prestigious journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.

In The Last Decade

Bryan A. Faller

30 papers receiving 527 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A

2022 128 citations Karen L. Reckamp, Mary W. Redman et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Bryan A. Faller United States	11	325	196	179	83	47	32	532
Jurjen J. Boonstra Netherlands	14	367 1.1×	205 1.0×	322 1.8×	121 1.5×	45 1.0×	49	781
Sonam Puri United States	12	324 1.0×	149 0.8×	176 1.0×	53 0.6×	67 1.4×	64	517
Nathalie Letarte Canada	10	221 0.7×	137 0.7×	141 0.8×	33 0.4×	52 1.1×	26	477
Marta Batus United States	13	296 0.9×	178 0.9×	243 1.4×	83 1.0×	74 1.6×	60	569
Yanshuo Cao China	13	367 1.1×	107 0.5×	181 1.0×	153 1.8×	47 1.0×	37	581
Pranshu Bansal United States	11	289 0.9×	121 0.6×	218 1.2×	62 0.7×	67 1.4×	21	510
Shinichiro Shimamatsu Japan	12	352 1.1×	175 0.9×	277 1.5×	89 1.1×	92 2.0×	40	580
Constanta Timcheva United Kingdom	9	384 1.2×	127 0.6×	94 0.5×	124 1.5×	21 0.4×	23	474
Stefania Oliva Italy	12	269 0.8×	315 1.6×	64 0.4×	50 0.6×	57 1.2×	23	578
Shiven B. Patel United States	12	276 0.8×	106 0.5×	168 0.9×	41 0.5×	61 1.3×	47	420

Countries citing papers authored by Bryan A. Faller

Since Specialization

Citations

This map shows the geographic impact of Bryan A. Faller's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan A. Faller with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan A. Faller more than expected).

Fields of papers citing papers by Bryan A. Faller

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan A. Faller. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan A. Faller. The network helps show where Bryan A. Faller may publish in the future.

Co-authorship network of co-authors of Bryan A. Faller

This figure shows the co-authorship network connecting the top 25 collaborators of Bryan A. Faller. A scholar is included among the top collaborators of Bryan A. Faller based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bryan A. Faller. Bryan A. Faller is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Dragnev, Konstantin H., Mary W. Redman, Karen L. Reckamp, et al.. (2025). PRAGMATICA-LUNG (SWOG S2302): A prospective, randomized study of ramucirumab plus pembrolizumab versus standard of care for participants previously treated with immunotherapy for stage IV or recurrent non-small cell lung cancer.. Journal of Clinical Oncology. 43(17_suppl).

Redman, Mary W., Hatim Husain, Karen L. Reckamp, et al.. (2024). Lung-MAP S1800D: A phase II/III study of N-803 (ALT-803) plus pembrolizumab versus standard of care in participants with stage IV or recurrent non-small cell lung cancer (NSCLC) previously treated with anti-PD-1 or anti-PD-L1 therapy.. Journal of Clinical Oncology. 42(16_suppl). 2619–2619. 2 indexed citations

Iyengar, Puneeth, Chen Hu, Daniel R. Gomez, et al.. (2024). NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology. 42(16_suppl). 8506–8506. 30 indexed citations

Mohamed, Mostafa, Kah Poh Loh, Supriya G. Mohile, et al.. (2023). External Validation of Risk Factors for Unplanned Hospitalization in Older Adults With Advanced Cancer Receiving Chemotherapy. Journal of the National Comprehensive Cancer Network. 21(3). 273–280.e3. 3 indexed citations

Hall, William A., Jiahe Li, Y. Nancy You, et al.. (2023). Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma. Journal of Clinical Oncology. 41(29). 4643–4651. 15 indexed citations

Ruddy, Kathryn J., David M. Zahrieh, Jun He, et al.. (2023). Dexamethasone to prevent everolimus-induced stomatitis (Alliance MIST Trial: A221701). Seminars in Oncology. 50(1-2). 7–10. 1 indexed citations

Reckamp, Karen L., Mary W. Redman, Konstantin H. Dragnev, et al.. (2022). Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A. Journal of Clinical Oncology. 40(21). 2295–2307. 128 indexed citations breakdown →

Reckamp, Karen L., Mary W. Redman, Konstantin H. Dragnev, et al.. (2022). Overall survival from a phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non–small cell lung cancer previously treated with immunotherapy: Lung-MAP nonmatched substudy S1800A.. Journal of Clinical Oncology. 40(16_suppl). 9004–9004. 8 indexed citations

Connolly, Roisín M., Fengmin Zhao, Kathy D. Miller, et al.. (2021). E2112: Randomized Phase III Trial of Endocrine Therapy Plus Entinostat or Placebo in Hormone Receptor–Positive Advanced Breast Cancer. A Trial of the ECOG-ACRIN Cancer Research Group. Journal of Clinical Oncology. 39(28). 3171–3181. 76 indexed citations

10.

Connolly, Roisín M., Fengmin Zhao, Kathy D. Miller, et al.. (2021). Abstract GS4-02: E2112: Randomized phase 3 trial of endocrine therapy plus entinostat/placebo in patients with hormone receptor-positive advanced breast cancer. A trial of the ECOG-ACRIN cancer research group. Cancer Research. 81(4_Supplement). GS4–2. 2 indexed citations

11.

Mohamed, Mostafa, Erika Ramsdale, Kah Poh Loh, et al.. (2021). Association of Polypharmacy and Potentially Inappropriate Medications With Physical Functional Impairments in Older Adults With Cancer. Journal of the National Comprehensive Cancer Network. 19(3). 267–274. 27 indexed citations

12.

Argiris, Athanassios, Jieling Miao, Mihaela Cristea, et al.. (2021). A Dose-finding Study Followed by a Phase II Randomized, Placebo-controlled Trial of Chemoradiotherapy With or Without Veliparib in Stage III Non–small-cell Lung Cancer: SWOG 1206 (8811). Clinical Lung Cancer. 22(4). 313–323.e1. 17 indexed citations

13.

Reckamp, Karen L., Mary W. Redman, Konstantin H. Dragnev, et al.. (2021). Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).. Journal of Clinical Oncology. 39(15_suppl). 9075–9075. 1 indexed citations

14.

Algazi, Alain P., Megan Othus, Adil Daud, et al.. (2020). Abstract CT013: SWOG S1320: Improved progression-free survival with continuous compared to intermittent dosing with dabrafenib and trametinib in patients with BRAF mutated melanoma. Cancer Research. 80(16_Supplement). CT013–CT013. 4 indexed citations

15.

Algazi, Alain P., Megan Othus, Adil Daud, et al.. (2020). Continuous versus intermittent BRAF and MEK inhibition in patients with BRAF-mutated melanoma: a randomized phase 2 trial. Nature Medicine. 26(10). 1564–1568. 67 indexed citations

16.

Algazi, Alain P., Megan Othus, Adil Daud, et al.. (2020). Association of prior immune checkpoint blockade (ICB) with longer progression-free survival (PFS) in patients treated with intermittent versus continuous dabrafenib and trametinib: A post-hoc analysis of S1320.. Journal of Clinical Oncology. 38(15_suppl). 10039–10039.

17.

Burtness, Barbara & Bryan A. Faller. (2009). Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy. Biologics. 419–419. 26 indexed citations

18.

Faller, Bryan A., et al.. (2009). Therapy-Related Acute Myelogenous Leukemia With an 11q23/MLL Translocation Following Adjuvant Cisplatin and Vinorelbine for Non–Small-Cell Lung Cancer. Clinical Lung Cancer. 10(6). 438–440. 7 indexed citations

19.

Faller, Bryan A. & John P. Atkinson. (2008). New-Onset Clubbing Associated with Lung Cancer. New England Journal of Medicine. 359(13). e15–e15. 3 indexed citations

20.

Faller, Bryan A., et al.. (2008). Anticoagulation and cardiac tamponade: Is there a relationship?. Journal of Clinical Oncology. 26(15_suppl). 9562–9562. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact